- 748 Downloads
Purpose of Review
Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.
In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple vertebral fractures is common or frequent (≥ 1/100 and < 1/10). In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab injection. Prescribing bisphosphonate before starting denosumab and/or after stopping denosumab may reduce this risk. However, only small case series have evaluated these strategies.
After the second denosumab dose, there is a rebound effect with an increased risk of multiple vertebral fractures. A potent bisphosphonate prescribed at denosumab discontinuation could reduce this risk. As denosumab discontinuation is characterized by many uncertainties, denosumab is a second-line treatment for osteoporosis. Studies are urgently needed to define the management of denosumab discontinuation.
KeywordsDenosumab discontinuation Osteoporosis Rebound effect Spontaneous multiple vertebral fractures
Compliance with Ethical Standards
Conflict of Interest
Olivier Lamy, Delphine Stoll, Bérengère Aubry-Rozier, and Elena Gonzalez Rodriguez declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 4.Miller PD, Bolognese MA, Lewiecki EM, et al ; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008;43:222–9.Google Scholar
- 5.•• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turn-over markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96:972–80 A well-detailed study on the biological and densitometric rebound effect at denosumab discontinuation. CrossRefPubMedGoogle Scholar
- 10.•• Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32:1291–6 The largest published observational study describing the characteristics of patients with multiple vertebral fractures after denosumab discontinuation. CrossRefPubMedGoogle Scholar
- 11.• Tripto-Shkolnik L, Rouach V, Marcus Y, Rotman-Pikielny P, Benbassat C, Vered I. Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. Calcif Tissue Int. 2018;103:44–9 An observational study that questioned the efficacy of bisphosphonates prescribed before denosumab to avoid the rebound effect upon discontinuation. CrossRefPubMedGoogle Scholar
- 12.•• Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33:190–8 Post hoc analysis of a randomized trial that describes the high incidence of multiple vertebral fractures at denosumab discontinuation, despite very short follow-up. CrossRefPubMedGoogle Scholar
- 15.Chapurlat R. Effects and management of denosumab discontinuation. Joint Bone Spine. 2018. https://doi.org/10.1016/j.jbspin.2017.12.013.
- 18.Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Hans D, Lamy O. Clinical features of 35 patients with 172 spontaneous vertebral fractures after denosumab discontinuation: a single center observational study. Osteoporos Int. 2018;(suppl 1):P637.Google Scholar
- 19.Fernandez E, Benavent D, Bonilla G, Monjo I, Garcia S, Bernad M, et al. Rebound-associated multiple vertebral fractures after discontinuation of denosumab: nine cases report. Ann Rheum Dis. 2018;(suppl):A450.Google Scholar
- 20.Florez H, Ramirez J, Monegal A, Guanabens N, Peris P. Spontaneous vertebral fractures after denosumab discontinuation: a report of 7 cases. Ann Rheum Dis. 2018;(suppl):A447.Google Scholar
- 35.McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–31.Google Scholar